Natalie M Reizine1,2, Keith Danahey2,3, Tien M Truong1,2, David George2,4, Larry K House1,2, Theodore G Karrison5, Xander M R van Wijk2,4,6, Kiang-Teck J Yeo2,4,6, Mark J Ratain1,2,6, Peter H O'Donnell1,2,6. 1. Section of Hematology/Oncology, Department of Medicine, University of Chicago Medical Center and Biological Sciences, Chicago, Illinois. 2. Center for Personalized Therapeutics, University of Chicago, Chicago, Illinois. 3. Center for Research Informatics, University of Chicago, Chicago, Illinois. 4. Department of Pathology, University of Chicago Medical Center and Biological Sciences, Chicago, Illinois. 5. Department of Public Health Sciences, University of Chicago, Chicago, Illinois. 6. Committee on Clinical Pharmacology and Pharmacogenomics, University of Chicago, Chicago, Illinois.
Abstract
BACKGROUND: In recent years, there has been increasing evidence supporting the role of germline pharmacogenomic factors predicting toxicity for anticancer therapies. Although somatic genomic data are used frequently in oncology care planning, germline pharmacogenomic testing is not. This study hypothesizes that comprehensive germline pharmacogenomic profiling could have high relevance for cancer care. METHODS: Between January 2011 and August 2020, patients at the University of Chicago Medical Center were genotyped across custom germline pharmacogenomic panels for reasons unrelated to cancer care. Actionable anticancer pharmacogenomic gene/drug interactions identified by the FDA were defined including: CYP2C9 (erdafitinib), CYP2D6 (gefitinib), DPYD (5-fluorouracil and capecitabine), TPMT (thioguanine and mercaptopurine), and UGT1A1 (belinostat, irinotecan, nilotinib, pazopanib, and sacituzumab-govitecan hziy). The primary objective was to determine the frequency of individuals with actionable or high-risk genotypes across these 5 key pharmacogenes, thus potentially impacting prescribing for at least 1 of these 11 commonly prescribed anticancer therapies. RESULTS: Data from a total of 1586 genotyped individuals were analyzed. The oncology pharmacogene with the highest prevalence of high-risk, actionable genotypes was UGT1A1, impacting 17% of genotyped individuals. Actionable TPMT and DPYD genotypes were found in 9% and 4% of patients, respectively. Overall, nearly one-third of patients genotyped across all 5 genes (161/525, 31%) had at least one actionable genotype. CONCLUSIONS: These data suggest that germline pharmacogenomic testing for 5 key pharmacogenes could identify a substantial proportion of patients at risk with standard dosing, an estimated impact similar to that of somatic genomic profiling. LAY SUMMARY: Differences in our genes may explain why some drugs work safely in certain individuals but can cause side effects in others. Pharmacogenomics is the study of how genetic variations affect an individual's response to medications. In this study, an evaluation was done for important genetic variations that can affect the tolerability of anticancer therapy. By analyzing the genetic results of >1500 patients, it was found that nearly one-third have genetic variations that could alter recommendations of what drug, or how much of, an anticancer therapy they should be given. Performing pharmacogenomic testing before prescribing could help to guide personalized oncology care.
BACKGROUND: In recent years, there has been increasing evidence supporting the role of germline pharmacogenomic factors predicting toxicity for anticancer therapies. Although somatic genomic data are used frequently in oncology care planning, germline pharmacogenomic testing is not. This study hypothesizes that comprehensive germline pharmacogenomic profiling could have high relevance for cancer care. METHODS: Between January 2011 and August 2020, patients at the University of Chicago Medical Center were genotyped across custom germline pharmacogenomic panels for reasons unrelated to cancer care. Actionable anticancer pharmacogenomic gene/drug interactions identified by the FDA were defined including: CYP2C9 (erdafitinib), CYP2D6 (gefitinib), DPYD (5-fluorouracil and capecitabine), TPMT (thioguanine and mercaptopurine), and UGT1A1 (belinostat, irinotecan, nilotinib, pazopanib, and sacituzumab-govitecan hziy). The primary objective was to determine the frequency of individuals with actionable or high-risk genotypes across these 5 key pharmacogenes, thus potentially impacting prescribing for at least 1 of these 11 commonly prescribed anticancer therapies. RESULTS: Data from a total of 1586 genotyped individuals were analyzed. The oncology pharmacogene with the highest prevalence of high-risk, actionable genotypes was UGT1A1, impacting 17% of genotyped individuals. Actionable TPMT and DPYD genotypes were found in 9% and 4% of patients, respectively. Overall, nearly one-third of patients genotyped across all 5 genes (161/525, 31%) had at least one actionable genotype. CONCLUSIONS: These data suggest that germline pharmacogenomic testing for 5 key pharmacogenes could identify a substantial proportion of patients at risk with standard dosing, an estimated impact similar to that of somatic genomic profiling. LAY SUMMARY: Differences in our genes may explain why some drugs work safely in certain individuals but can cause side effects in others. Pharmacogenomics is the study of how genetic variations affect an individual's response to medications. In this study, an evaluation was done for important genetic variations that can affect the tolerability of anticancer therapy. By analyzing the genetic results of >1500 patients, it was found that nearly one-third have genetic variations that could alter recommendations of what drug, or how much of, an anticancer therapy they should be given. Performing pharmacogenomic testing before prescribing could help to guide personalized oncology care.
Authors: Mary V Relling; Matthias Schwab; Michelle Whirl-Carrillo; Guilherme Suarez-Kurtz; Ching-Hon Pui; Charles M Stein; Ann M Moyer; William E Evans; Teri E Klein; Federico Guillermo Antillon-Klussmann; Kelly E Caudle; Motohiro Kato; Allen E J Yeoh; Kjeld Schmiegelow; Jun J Yang Journal: Clin Pharmacol Ther Date: 2019-01-20 Impact factor: 6.875
Authors: Daniel V T Catenacci; Leah Chase; Samantha Lomnicki; Theodore Karrison; Robert de Wilton Marsh; Murtuza M Rampurwala; Sunil Narula; Lindsay Alpert; Namrata Setia; Shu-Yuan Xiao; John Hart; Uzma D Siddiqui; Bryan Peterson; Kelly Moore; Kristin Kipping-Johnson; Ugne Markevicius; Barbara Gordon; Kenisha Allen; Christine Racette; Steven B Maron; Chih-Yi Liao; Blase N Polite; Hedy L Kindler; Kiran Turaga; Vivek N Prachand; Kevin K Roggin; Mark K Ferguson; Mitchell C Posner Journal: JAMA Netw Open Date: 2020-02-05
Authors: Lori Kay Mattison; Jeanne Fourie; Renee A Desmond; Anil Modak; Muhammad Wasif Saif; Robert B Diasio Journal: Clin Cancer Res Date: 2006-09-15 Impact factor: 12.531
Authors: F Mosele; J Remon; J Mateo; C B Westphalen; F Barlesi; M P Lolkema; N Normanno; A Scarpa; M Robson; F Meric-Bernstam; N Wagle; A Stenzinger; J Bonastre; A Bayle; S Michiels; I Bièche; E Rouleau; S Jezdic; J-Y Douillard; J S Reis-Filho; R Dienstmann; F André Journal: Ann Oncol Date: 2020-08-24 Impact factor: 32.976
Authors: Linda M Henricks; Carin A T C Lunenburg; Femke M de Man; Didier Meulendijks; Geert W J Frederix; Emma Kienhuis; Geert-Jan Creemers; Arnold Baars; Vincent O Dezentjé; Alexander L T Imholz; Frank J F Jeurissen; Johanna E A Portielje; Rob L H Jansen; Paul Hamberg; Albert J Ten Tije; Helga J Droogendijk; Miriam Koopman; Peter Nieboer; Marlène H W van de Poel; Caroline M P W Mandigers; Hilde Rosing; Jos H Beijnen; Erik van Werkhoven; André B P van Kuilenburg; Ron H N van Schaik; Ron H J Mathijssen; Jesse J Swen; Hans Gelderblom; Annemieke Cats; Henk-Jan Guchelaar; Jan H M Schellens Journal: Lancet Oncol Date: 2018-10-19 Impact factor: 41.316
Authors: Nga Yeung Tang; Xun Pei; David George; Larry House; Keith Danahey; Elizabeth Lipschultz; Mark J Ratain; Peter H O'Donnell; Kiang-Teck J Yeo; Xander M R van Wijk Journal: J Appl Lab Med Date: 2021-11-01
Authors: H Fang; X Liu; J Ramírez; N Choudhury; M Kubo; H K Im; A Konkashbaev; N J Cox; M J Ratain; Y Nakamura; P H O'Donnell Journal: Pharmacogenomics J Date: 2014-07-01 Impact factor: 3.550
Authors: Minoli A Perera; Peter H O'Donnell; Wenndy Hernandez; Keith Danahey; Xun Pei; Kiang-Teck J Yeo; Edward Leung; Samuel L Volchenboum; Mark J Ratain; David O Meltzer; Barbara E Stranger Journal: Pharmacogenomics J Date: 2019-09-11 Impact factor: 3.550